Aegerion Pharmaceuticals Inc. (AEGR) Stock Rating Reaffirmed by Cowen and Company
Aegerion Pharmaceuticals Inc. (NASDAQ:AEGR)‘s stock had its “hold” rating restated by research analysts at Cowen and Company in a research report issued to clients and investors on Wednesday. They currently have a $1.50 price objective on the biopharmaceutical company’s stock. Cowen and Company’s target price indicates a potential downside of 23.86% from the stock’s previous close.
The analysts wrote, “Due to the November 29, 2016 merger of Aegerion Pharmaceuticals, Inc.””
AEGR has been the topic of a number of other research reports. Zacks Investment Research raised Aegerion Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, October 19th. JPMorgan Chase & Co. started coverage on Aegerion Pharmaceuticals in a report on Friday, November 11th. They issued a “hold” rating on the stock. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and three have given a buy rating to the company’s stock. Aegerion Pharmaceuticals presently has an average rating of “Hold” and a consensus price target of $7.50.
Shares of Aegerion Pharmaceuticals (NASDAQ:AEGR) remained flat at $1.97 on Wednesday. Aegerion Pharmaceuticals has a 52-week low of $1.23 and a 52-week high of $10.85. The firm has a 50-day moving average of $1.94 and a 200-day moving average of $1.80. The firm’s market cap is $58.20 million.
ILLEGAL ACTIVITY WARNING: “Aegerion Pharmaceuticals Inc. (AEGR) Stock Rating Reaffirmed by Cowen and Company” was reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this news story on another site, it was illegally stolen and republished in violation of United States and international trademark and copyright legislation. The correct version of this news story can be viewed at https://www.thecerbatgem.com/2016/11/30/aegerion-pharmaceuticals-inc-aegr-stock-rating-reaffirmed-by-cowen-and-company.html.
In related news, major shareholder Healthcare Master Fun Broadfin bought 75,000 shares of the business’s stock in a transaction that occurred on Tuesday, September 13th. The stock was acquired at an average price of $1.75 per share, for a total transaction of $131,250.00. The purchase was disclosed in a document filed with the SEC, which is available through the SEC website. Insiders own 4.60% of the company’s stock.
Several institutional investors have recently bought and sold shares of AEGR. Scopia Capital Management LP bought a new position in Aegerion Pharmaceuticals during the third quarter valued at approximately $16,940,000. Sarissa Capital Management LP increased its position in shares of Aegerion Pharmaceuticals by 2.7% in the second quarter. Sarissa Capital Management LP now owns 2,649,000 shares of the biopharmaceutical company’s stock valued at $3,947,000 after buying an additional 69,000 shares during the last quarter. Artal Group S.A. acquired a new position in shares of Aegerion Pharmaceuticals during the second quarter valued at about $1,490,000. Jefferies Group LLC increased its position in shares of Aegerion Pharmaceuticals by 149.9% in the second quarter. Jefferies Group LLC now owns 745,150 shares of the biopharmaceutical company’s stock valued at $1,110,000 after buying an additional 447,027 shares during the last quarter. Finally, Spark Investment Management LLC increased its position in shares of Aegerion Pharmaceuticals by 10.1% in the second quarter. Spark Investment Management LLC now owns 586,400 shares of the biopharmaceutical company’s stock valued at $873,000 after buying an additional 53,600 shares during the last quarter. Institutional investors and hedge funds own 84.87% of the company’s stock.
About Aegerion Pharmaceuticals
Aegerion Pharmaceuticals, Inc is a biopharmaceutical company engaged in the development and commercialization of therapies for patients with debilitating rare diseases. It operates through pharmaceuticals segment. Its products include lomitapide and metreleptin. Lomitapide is a small molecule microsomal triglyceride transfer protein (MTP) inhibitor.
Receive News & Stock Ratings for Aegerion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aegerion Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.